Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in G7 countries has been steadily growing in the past few years due to various factors.
Customer preferences: Patients suffering from rheumatoid arthritis and other related diseases are the primary customers of Anti-Rheumatic Drugs. These patients prefer drugs that provide quick relief from pain and inflammation, have minimal side effects, and are cost-effective.
Trends in the market: The Anti-Rheumatic Drugs market in the United States is the largest in the G7 region due to the high prevalence of rheumatoid arthritis and other autoimmune diseases. The market is expected to grow further due to the increasing aging population and the rise in the number of patients suffering from rheumatoid arthritis. The market in Japan is also growing due to the high prevalence of rheumatoid arthritis and the availability of advanced treatment options. In Europe, the market is driven by the increasing awareness about rheumatoid arthritis and the availability of biosimilars.
Local special circumstances: In Canada, the Anti-Rheumatic Drugs market is highly regulated, and the prices of drugs are controlled by the government. This has resulted in a limited number of drugs being available in the market. In France, the market is dominated by biosimilars due to the government's policy of promoting the use of biosimilars. In Italy, the market is highly fragmented, and there are many small players operating in the market.
Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in G7 countries is driven by the increasing prevalence of rheumatoid arthritis and other autoimmune diseases. The aging population is also a significant factor as the prevalence of these diseases increases with age. The availability of advanced treatment options, such as biologics and biosimilars, has also contributed to the growth of the market. The increasing healthcare expenditure and the availability of health insurance have made these drugs more accessible to the patients. However, the high cost of biologics is a significant barrier to the growth of the market. The government's policies and regulations also play a crucial role in shaping the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
